Renal comorbidity after solid organ and stem cell transplantation

Am J Transplant. 2012 Jul;12(7):1691-9. doi: 10.1111/j.1600-6143.2012.04047.x. Epub 2012 Apr 9.

Abstract

After transplantation of solid organs or hematopoietic stem cells, a significant acute decrease in renal function occurs in the majority of patients. Depending on the degree of kidney injury, a large number of patients develop chronic kidney disease (CKD) and some develop end-stage renal disease requiring renal replacement therapy. The incidence varies depending on the transplanted organ, but important risk factors for the development of CKD are preexisting renal disease, hepatitis C, diabetes, hypertension, age, sex, posttransplant acute kidney injury and thrombotic microangiopathy. This review article focuses on the risk factors of posttransplant chronic kidney disease after organ transplantation, considering the current literature and integrates the incidence and the associated mortality rates of acute and chronic kidney disease. Furthermore, we introduce the RECAST (REnal Comorbidity After Solid organ and hematopoietic stem cell Transplantation) registry.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Kidney Diseases / etiology*
  • Organ Transplantation / adverse effects*